Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 13,915 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Chronic Musculoskeletal Disease
Interventions: Acceptance and Committment Therapy; Behavioral
Lead sponsor: University of New Hampshire; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, New Hampshire

Conditions: Insomnia
Interventions: PD 0200390, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Presbyopia
Interventions: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 40 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 10
States / cities: Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more

Conditions: COVID-19
Interventions: Lopinavir/Ritonavir 400 mg/100 mg, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 3 more

Conditions: Supracondylar Humerus Fracture
Interventions: Ibuprofen, Oxycodone, Acetaminophen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 4 Years to 12 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions: Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab); Biological · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Diabetes Mellitus
Interventions: FK614; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 36
States / cities: Ozark, Alabama • Tucson, Arizona • Cypress, California + 29 more

Conditions: Adolescent Behavior, Violence in Adolescence, Group, Peer, Violence, Non-accidental, Violence, Sexual, Violence, Physical, Violence, Domestic, Emotional Abuse, Coping Skills, Communication, Personal
Interventions: Expect Respect, Enhanced Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 11 Years to 15 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Suicide, Depressive Disorder, Major, Anxiety Disorders, Suicidal Ideation, Suicidal Impulses
Interventions: Standard of Care, Crisis Intervention, Wraparound Services; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 10 Years to 18 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Deep Full-thickness Burn Injury (Disorder)
Interventions: realSKIN (skin xenotransplant), Human Cadaver Allograft; Biological
Lead sponsor: XenoTherapeutics, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Augusta, Georgia • Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Pedometer, Educational materials, Step count goals; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Scar, Skin Scarring, Skin Cancer, Wound Heal, Wound of Skin, Surgical Wound, Patient Satisfaction, Patient Preference, Surgical Incision
Interventions: Hydrocolloid dressing, Petrolatum jelly dressing; Device · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Logopenic Progressive Aphasia, Primary Progressive Aphasia
Interventions: High-definition active tDCS (HD-tDCS) + "Repeat After Me" (RAM) Treatment, Sham + "Repeat After Me" (RAM) Treatment; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Normal Pressure Hydrocephalus (INPH)
Interventions: programmable CSF shunt valve; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Davis, California • Los Angeles, California • Santa Monica, California + 10 more

Conditions: Hernia Incisional, Suture, Complication
Interventions: Duramesh Laparotomy Closure, Conventional suture closure; Device
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Neuropathic Pain
Interventions: Auricular acupuncture; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Inflammatory Bowel Disease
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 19 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Nutrition, Diet Interventions
Interventions: Control label, Added sugar warning; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Analgesic Efficacy
Interventions: Suzetrigine, acetaminophen; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions: Neuropeptide Y, Placebo; Drug · Other
Lead sponsor: New York Medical College; Other
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Valhalla, New York

Conditions: Migraine
Interventions: Saline, lidocaine/bupivacaine; Drug · Combination Product
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Zinc, Placebos for zinc and nicotinamide riboside, Nicotinamide riboside; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: ADHD
Interventions: Placebo, 200mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Dothan, Alabama • Orange, California • Hialeah, Florida + 9 more

Search by objective public record fields.

Acceptance and Commitment Therapy, a Mindfulness-Based Approach for Treatment of Chronic Musculoskeletal Pain

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19

Supracondylar Post-Operative Pain Study

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

Expect Respect Middle School Randomized Trial

Promote Access to Stop Suicide: Comparison of Follow up Services for Youth at Risk for Suicide

Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds

Trial of a Physical Activity Intervention for RA Fatigue

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment

Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA

Efficacy in iNPH Shunting (PENS) Trial

DuraMesh Laparotomy Closure Following Trauma and Emergency Surgery

Ear Acupuncture for Neuropathic Pain

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

Impacts of Sugar Warnings on Weight Bias

Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD